Your browser is no longer supported. Please, upgrade your browser.
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E21.42 EPS (ttm)10.22 Insider Own0.66% Shs Outstand148.00M Perf Week-3.09%
Market Cap32.95B Forward P/E11.64 EPS next Y18.80 Insider Trans0.00% Shs Float145.87M Perf Month-7.22%
Income1.55B PEG- EPS next Q3.34 Inst Own86.60% Short Float1.69% Perf Quarter-15.78%
Sales11.10B P/S2.97 EPS this Y-21.10% Inst Trans0.02% Short Ratio1.54 Perf Half Y-33.49%
Book/sh70.47 P/B3.11 EPS next Y-1.78% ROA6.40% Target Price282.23 Perf Year-18.27%
Cash/sh19.64 P/C11.15 EPS next 5Y-15.00% ROE14.50% 52W Range214.88 - 468.55 Perf YTD-8.74%
Dividend- P/FCF13.63 EPS past 5Y10.10% ROI19.60% 52W High-53.27% Beta0.46
Dividend %- Quick Ratio1.40 Sales past 5Y4.50% Gross Margin82.50% 52W Low1.89% ATR8.55
Employees9100 Current Ratio1.70 Sales Q/Q-17.70% Oper. Margin17.30% RSI (14)38.42 Volatility3.38% 3.80%
OptionableYes Debt/Eq0.70 EPS Q/Q-50.40% Profit Margin13.90% Rel Volume0.66 Prev Close219.60
ShortableYes LT Debt/Eq0.60 EarningsOct 20 BMO Payout0.00% Avg Volume1.60M Price218.94
Recom2.30 SMA20-6.62% SMA50-7.89% SMA200-24.90% Volume1,102,108 Change-0.30%
Jan-13-22Downgrade Guggenheim Buy → Neutral $290 → $202
Jan-12-22Downgrade Piper Sandler Overweight → Neutral $362 → $216
Dec-10-21Resumed Raymond James Mkt Perform
Dec-09-21Resumed Wells Fargo Equal Weight $250
Dec-06-21Initiated Goldman Neutral $271
Nov-19-21Initiated BMO Capital Markets Outperform $315
Sep-23-21Initiated Needham Buy $400
Jun-18-21Upgrade Piper Sandler Neutral → Overweight $384 → $450
Jun-14-21Reiterated Truist Buy $458 → $647
Jun-11-21Upgrade Bernstein Mkt Perform → Outperform $500
Jun-10-21Upgrade UBS Neutral → Buy
Jun-08-21Upgrade William Blair Mkt Perform → Outperform
Jun-08-21Upgrade Robert W. Baird Underperform → Neutral $216 → $382
Jun-08-21Upgrade Citigroup Sell → Neutral $200 → $440
Jun-08-21Upgrade Atlantic Equities Underweight → Neutral $415
Jun-08-21Reiterated Stifel Buy $346 → $446
Jun-08-21Reiterated RBC Capital Mkts Sector Perform $259 → $400
Jun-08-21Reiterated Morgan Stanley Overweight $343 → $455
Jun-08-21Reiterated Jefferies Buy $450 → $500
Jun-08-21Reiterated H.C. Wainwright Buy $305 → $452
Jan-27-22 08:27PM  
07:15PM  
07:10PM  
06:50PM  
05:38PM  
05:38PM  
03:25PM  
03:01PM  
01:38PM  
09:43AM  
07:30AM  
Jan-26-22 05:38PM  
01:38PM  
09:38AM  
09:38AM  
Jan-25-22 05:50PM  
12:33PM  
09:38AM  
Jan-24-22 06:00PM  
05:38PM  
09:38AM  
Jan-23-22 11:05AM  
Jan-22-22 10:00AM  
Jan-21-22 07:00PM  
05:38PM  
01:38PM  
07:00AM  
Jan-18-22 01:38PM  
09:41AM  
09:38AM  
09:07AM  
Jan-17-22 06:40AM  
Jan-15-22 06:36AM  
Jan-14-22 06:00PM  
05:38PM  
10:11AM  
06:10AM  
Jan-13-22 09:38PM  
04:08PM  
03:34PM  
03:32PM  
01:10PM  
11:27AM  
09:03AM  
08:33AM  
08:20AM  
08:01AM  
Jan-12-22 05:38PM  
04:06PM  
01:15PM  
01:12PM  
11:32AM  
11:30AM  
11:10AM  
11:05AM  
11:01AM  
10:34AM  
10:14AM  
10:13AM  
10:13AM  
10:02AM  
09:44AM  
09:33AM  
09:08AM  
08:11AM  
07:21AM  
06:53AM  
06:50AM  
06:49AM  
05:14AM  
03:04AM  
01:43AM  
12:52AM  
12:48AM  
Jan-11-22 07:04PM  
06:55PM  
05:01PM  
04:58PM  
04:49PM  
02:05PM  
07:00AM  
Jan-10-22 12:10PM  
12:00PM  
07:00AM  
04:15AM  
Jan-07-22 05:38PM  
03:46PM  
06:37AM  
05:10AM  
Jan-06-22 05:36AM  
05:30AM  
Jan-05-22 05:50PM  
12:10PM  
11:20AM  
Jan-04-22 03:30PM  
08:50AM  
07:34AM  
07:30AM  
Jan-03-22 06:00PM  
06:19AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kramer RobinChief Accounting OfficerDec 03Option Exercise223.9233975,9091,210Dec 07 04:09 PM
Izzar RachidHead of Alzheimer's DiseaseDec 02Option Exercise228.5237285,0091,271Dec 06 04:14 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise338.246,0052,031,1314,864Sep 03 04:08 PM
Sandrock AlfredHead of Research & DevelopmentJun 07Sale440.007,6723,375,68010,169Jun 09 07:05 PM
Guindo ChirfiHead of Glob Prod Strat & ComJun 07Sale440.003,0871,358,2802,919Jun 09 07:04 PM
Posner Brian SDirectorJun 04Sale274.1736098,7017,400Jun 07 07:02 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.004,454019,715Feb 17 05:01 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0016,289060,194Feb 17 05:03 PM
Kramer RobinSVP, Chief Accounting OfficerFeb 12Option Exercise0.003330706Feb 17 04:59 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.003,15606,946Feb 17 04:58 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.002,92309,288Feb 17 04:56 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,57304,765Feb 17 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.004,355043,509Feb 17 04:52 PM
Mantas Jesus BDirectorFeb 09Buy267.00898239,7662,943Feb 10 04:31 PM